Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for H.U. Group Holdings Inc. (4544:JPX), powered by AI.
H.U. Group Holdings Inc. is currently trading at ¥3,190. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for H.U. Group Holdings Inc. on Alpha Lenz.
H.U. Group Holdings Inc.'s P/E ratio is 65.7.
“H.U. Group Holdings Inc. trades at a P/E of 65.7 (premium valuation) with modest ROE of 2.0%.”
Ask for details →H.U. Group Holdings Inc. is a leading company in the healthcare and diagnostics sector, primarily focused on clinical testing, diagnostics, and related services. The company provides comprehensive laboratory services, including testing for a wide array of medical conditions, ranging from routine blood tests to sophisticated genetic analyses. H.U. Group Holdings also supplies diagnostic products and develops innovative testing solutions, contributing significantly to the healthcare industry's capacity to deliver precise and timely diagnosis. The firm plays a crucial role in advancing medical research and public health through its services, impacting both healthcare providers and patients alike. By maintaining robust testing capabilities and fostering technological advancements, H.U. Group Holdings supports healthcare systems in managing and combating diseases more effectively. As a key player in the healthcare market, it serves hospitals, clinics, and various other healthcare institutions, ensuring they have access to essential diagnostic tools and information. Founded in Japan, H.U. Group Holdings continues to expand its influence, underpinning its essential role in global healthcare infrastructure with a commitment to quality and innovation.
“H.U. Group Holdings Inc. trades at a P/E of 65.7 (premium valuation) with modest ROE of 2.0%.”
Ask for details →H.U. Group Holdings Inc. (ticker: 4544) is a company listed on JPX in the Healthcare sector (Diagnostics & Research). It has approximately 5,444 employees. Market cap is $181.2B.
The current price is 3,190 with a P/E ratio of 65.66x and P/B of 1.32x.
ROE is 1.97% and operating margin is 1.09%. Annual revenue is $243.0B.